Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up
Mainstay Medical Holdings plc today announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial. There were 126 patients who completed the 5-year follow up, and the published data clearly indicated that ReActiv8® Restorative Neurostimulation is a long-term, effective, durable, and safe therapy. ReActiv8 is the only restorative therapy for patients suffering from non-surgical, mechanical CLBP evidenced by multifidus dysfunction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319164677/en/
The long-term responses across pain, disability, and health-related quality of life measures are shown in the following graphs. (Graphic: Business Wire)
The publication is available here:
https://www.sciencedirect.com/science/article/pii/S1094715924000552
The ReActiv8-B study saw multiple patients have their implants removed for resolution of back pain. These removals for success suggest a restorative mechanism, and the therapy shows no evidence of the loss of efficacy commonly observed with palliative treatments.
Dr. Chris Gilligan, Chief Medical Officer and Chief Quality Officer at Robert Wood Johnson University Hospital, stated: “The long-term, durable patient outcomes from this study are unprecedented in the field of neuromodulation. This is truly a unique therapy that is restorative in nature and does not show any of the loss of efficacy seen with other treatments in our field. With 5 year published outcomes, we are no longer limited to providing temporary or palliative treatments to our patients. ReActiv8 is changing the way we treat properly selected patients.”
Jason Hannon, CEO of Mainstay Medical, stated: "We are proud to have the only commercially available device with a strong safety profile and long-term, peer-reviewed evidence supporting the rehabilitation of this severely affected patient population. We look forward to sharing this data with our physician customers and their patients, as well as using it to further engage managed care organizations in the United States to expand commercial insurance access to this incredible therapy.”
About ReActiv8®
ReActiv8 is an implantable medical device designed to treat adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. Multifidus muscle dysfunction may be evidenced by imaging or physiological testing in adults who have failed therapy including pain medications and physical therapy, and who are not candidates for spine surgery. ReActiv8 has received regulatory approval in several geographic areas, and is commercially available in the European Economic Area, Australia, the UK, and the US.
About Mainstay Medical
Mainstay Medical is a medical device company focused on commercializing its innovative implantable Restorative Neurostimulation system, ReActiv8, for people with disabling mechanical CLBP. Mainstay Medical is headquartered in Dublin, Ireland and has subsidiaries operating in Ireland, the United States, Australia, Germany, and the Netherlands.
Further information can be found at www.mainstaymedical.com.
Mainstay Forward-Looking Statements
All statements in this announcement other than statements of historical fact are, or may be deemed to be, forward-looking statements. These forward-looking statements may include, without limitation, statements regarding the company’s intentions, beliefs or current expectations concerning, among other things, the company’s clinical outcomes, commercial efforts and performance, research studies and results, financial position, financing strategies, product design and development, intellectual property portfolio and its scope, regulatory applications and approvals, and reimbursement arrangements.
Forward-looking statements involve risk and uncertainty and are not guarantees of future performance. Actual results may differ materially from those described in, or suggested by, the forward-looking statements. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements herein, including, without limitation, the risks and uncertainties included in the company’s Annual Report for the year ended 31 December 2022, which should be read in conjunction with the company’s public disclosures (available on the company’s website (www.mainstaymedical.com)). The forward-looking statements herein speak only as of the date of this announcement.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240319164677/en/
Contact information
Mainstay PR and IR Enquiries:
L
ifeSci Advisors, LLC
Brian Ritchie
Tel: + 1 (212) 915-2578
Email: britchie@lifesciadvisors.com
FTI Consulting (for Ireland)
Jonathan Neilan or Patrick Berkery
Tel. : +353 86 602 5988
Email: mainstay@fticonsulting.com
Mainstay Medical
Corporate Communications
Email: Media@mainstaymedical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
iFIT Expands Global Reach with Rollout of AI Coach in 19 Countries2.6.2025 16:00:00 EEST | Press release
iFIT Inc., a global leader in connected fitness and interactive content, today announced the expansion of its iFIT AI Coach (beta) across 19 countries: Australia, Austria, Belgium, Canada, Finland, France, Germany, Ireland, Italy, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and the UK. This strategic expansion brings iFIT’s intelligent, personalized fitness technology to more athletes around the globe. AI Coach is iFIT’s most advanced digital training tool to date, leveraging proprietary technology and user data to deliver hyper-personalized fitness and wellness plans. The tool adapts dynamically to users' goals, schedules, and performance, offering real-time feedback and motivation across a wide range of fitness categories—from strength and cardio to recovery and mindfulness. “Expanding iFIT AI Coach beyond the U.S. reflects our mission to make intelligent, interactive fitness more accessible around the globe,” said Bart Mueller, Chief I
12BET Makes the Shortlist at the 2025 EGR Marketing & Innovation Awards2.6.2025 15:16:00 EEST | Press release
12BET, a pioneering name in the igaming world since 2007, is honored to be shortlisted in two categories at the 2025 EGR Marketing & Innovation Awards: Sportsbook Marketing Campaign, and Marketing Team of the Year – B2C. This recognition highlights the brand’s ongoing dedication to creating meaningful and original experiences that resonate with sports audiences and digital communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250519535436/en/ The EGR Marketing & Innovation Awards are among the most respected accolades in the online gaming industry. Held annually, the awards celebrate creativity, strategic thinking, and innovation across the sector, attracting participation from many of the world’s leading companies. For 12BET, being named a finalist is a meaningful milestone that showcases the brand’s energy, originality, and deep-rooted passion for sports culture. 12BET’s approach to creativity is rooted in connection
Adtran expands Oscilloquartz atomic clock portfolio with lower-cost optical cesium solutions for wider market adoption2.6.2025 15:00:00 EEST | Press release
Adtran today launched the latest additions to its Oscilloquartz optical cesium portfolio, expanding access to precision timing across a wider range of network environments. The new OSA 3200 SP and OSA 3250 ePRC leverage advanced optical pumping technology, offering improved holdover, simplified maintenance and a typical lifetime of 10 years. Built on the same proven platform as Adtran’s high-end cesium models, the solutions enable telecom operators, data centers, power utilities and defense networks to modernize synchronization infrastructure while lowering operational complexity and cost. The new models also address industry demand for alternatives to legacy magnetic cesium clocks that are more difficult to manage over time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530192819/en/ Adtran’s OSA 3200 SP and OSA 3250 ePRC will bring lower-cost optical pumping cesium technology to new markets and applications. “We develo
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 14:00:00 EEST | Press release
Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expertise across its diverse learner and corporate partner network. Massie continued, “With a network of over 30 manufacturing sites across nine
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 14:00:00 EEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom